Article
Immunology
Mona Tarighi, Mehdi Shahbazi, Payam Saadat, Abdolreza Daraei, Ali Alizadeh Khatir, Kimiya Rahimifard, Mousa Mohammadnia-Afrouzi
Summary: This study examined the frequency and gene expression levels of regulatory T cells (Tregs) in secondary progressive multiple sclerosis (SPMS) patients. The results showed that the percentage of Tregs with CD4 and CD25 markers did not differ significantly compared to healthy controls, but the lymphocytes with CD4/CD25/FOXP3/Helios markers were significantly reduced in SPMS patients. The expression of the Helios gene was also decreased in these patients. These findings suggest that a deficiency in Tregs may be involved in the immunological mechanisms of SPMS.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Immunology
Ting-Wei Lin, Ya-Chiao Hu, Yao-Hsu Yang, Yin-Hsiu Chien, Ni-Chung Lee, Hsin-Hui Yu, Bor-Luen Chiang, Li-Chieh Wang
Summary: We reported a case of a patient with multiple disorders, including autoimmune disease, immunodeficiency, enteropathy, organomegaly and lymphocytic infiltration. The patient showed excellent response to abatacept treatment.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2022)
Article
Rheumatology
Alyxzandria M. Gaydosik, Tracy Tabib, Robyn Domsic, Dinesh Khanna, Robert Lafyatis, Patrizia Fuschiotti
Summary: Through single-cell transcriptome analysis, different subsets of T cells in healthy and SSc skin were identified, each associated with distinct signaling pathways. A unique subset of recirculating CXCL13(+) T cells in SSc skin was discovered, expressing a T helper follicular-like gene expression signature and potentially promoting B-cell responses in the inflamed skin of patients.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Immunology
Gavin Giovannoni, Patricia K. Coyle, Patrick Vermersch, Bryan Walker, Julie Aldridge, Axel Nolting, Andrew Galazka, Caroline Lemieux, Thomas P. Leist
Summary: The study found that CladT3.5 had a similar effect on ALC and lymphocyte subsets in both younger and older patient groups, with lymphocyte levels recovering to normal range soon after treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Satomi Kobayashi, Yasuo Nagafuchi, Mai Okubo, Yusuke Sugimori, Hiroaki Hatano, Saeko Yamada, Masahiro Nakano, Ryochi Yoshida, Yusuke Takeshima, Mineto Ota, Yumi Tsuchida, Yukiko Iwasaki, Keigo Setoguchi, Kanae Kubo, Tomohisa Okamura, Kazuhiko Yamamoto, Hirofumi Shoda, Keishi Fujio
Summary: RNA-seq of immune cells indicated the dysregulation of Fr. II eTregs in early SSc with increased proportion of the activated subpopulation.
Article
Immunology
Qing Li, Chunlei Feng, Lingyun Li, Guiliang Xu, Haijuan Gu, Shiqiang Li, Dali Li, Mingyao Liu, Shuhua Han, Biao Zheng
Summary: This study demonstrates the important role of Lp-PLA(2) in controlling inflammatory macrophage polarization in autoimmune encephalomyelitis and multiple sclerosis. Lp-PLA(2) affects M1 function through lysophosphatidylcholine-mediated pathways and G2A receptor guidance, which could potentially lead to new therapeutic approaches for MS and other inflammatory disorders.
JOURNAL OF IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Flora Reverchon, Colleen Guillard, Lucile Mollet, Pascal Auzou, David Gosset, Fahima Madouri, Antoine Valery, Arnaud Menuet, Canan Ozsancak, Maud Pallix-Guyot, Severine Morisset-Lopez
Summary: This study reveals a dysregulation of 5-HT7 expression in natalizumab-treated multiple sclerosis (MS) patients, with an increase in 5-HT7 surface expression on T lymphocytes and CD4(+) T cell subsets. Activation of 5-HT7 receptor promotes the production of IL-10, suggesting its protective role in MS.
Review
Clinical Neurology
Borros Arneth
Summary: Multiple sclerosis (MS) is a complex autoimmune disorder characterized by neurologic dysfunction that worsens as the disease progresses. This study aimed to examine the role of T cells in MS pathogenesis, revealing significant link between MS and T cell activity. Targeting T cells is a potential strategy for the development of new therapies to manage MS, indicating the influence of effector T cells and regulatory T cells on MS development and progression.
JOURNAL OF NEUROLOGY
(2021)
Review
Immunology
Saige L. Pompura, David A. Hafler, Margarita Dominguez-Villar
Summary: Cellular metabolic remodeling is closely linked to the development, activation, differentiation, function, and survival of T cells, and specific lipid species can alter the function and metabolism of T cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Assaf Gottlieb, Hoai Phuong T. Pham, John William Lindsey
Summary: This study presents a method to stimulate T lymphocytes in multiple sclerosis patients and controls using non-suppressive brain homogenate. The results suggest that the brain-responding cells from MS patients may be pathogenic based on mRNA expression and their T-cell receptor repertoire shows minimal overlap with virus antigens.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Multidisciplinary Sciences
Andre Eduardo de Almeida Franzoi, Fernanda Subtil de Moraes Machado, Washigton Luiz Gomes de Medeiros Junior, Isabelle Pastor Bandeira, Wesley Nogueira Brandao, Marcus Vinicius Magno Goncalves
Summary: miRNAs play crucial roles in MS by regulating gene expression in various cells. NTZ treatment modifies gene expression and miRNA levels in B cells, indicating a potential for specific miRNAs to serve as markers of therapeutic response in MS patients. Understanding the complex interaction between miRNAs, gene expression in B cells, and therapeutic response is important for MS treatment.
Review
Immunology
Martina Kunkl, Carola Amormino, Valentina Tedeschi, Maria Teresa Fiorillo, Loretta Tuosto
Summary: This review summarizes the changes and behavior of astrocytes in multiple sclerosis and experimental autoimmune encephalomyelitis, as well as the contribution of pathogenic T cell subsets and CD8(+) T cells to astrocytic modifications and pathological outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
N. Eiza, M. Garty, E. Staun-Ram, A. Miller, Z. Vadasz
Summary: Research found that sema3A expression on Tregs and serum levels in MS patients were decreased, while sema4A levels were increased. Additionally, sema3A and sema4A were found to have positive/negative correlations with the severity of MS. Targeting sema3A and sema4A could be a potential therapeutic approach for MS.
CLINICAL IMMUNOLOGY
(2022)
Review
Cell Biology
Stefanie Fischer, Undine Proschmann, Katja Akguen, Tjalf Ziemssen
Summary: While the detailed pathogenesis of multiple sclerosis (MS) remains unclear, a range of disease-modifying therapies (DMTs) are available. A common side effect of almost every MS therapeutic agent is lymphopenia, which can have both beneficial and limiting effects on treatment. Understanding the mechanism of action of the selected agent is essential for comprehending treatment-associated changes in white blood cell counts and monitoring outcomes.
Article
Pharmacology & Pharmacy
Rong-Hong Guo, Hao Cheng, Xiao-Ying Zhang, Zhen Yu, Guang-Hui Wang, Shu-Ya Hao, Xiao-Peng Gao, Hong-Yan Wen
Summary: This study aimed to investigate the changes in absolute numbers of T-lymphocyte subsets and serum cytokines in patients with systemic sclerosis (SSc). The study found that patients with SSc had lower numbers of Th2 and Treg cells compared to healthy controls, which led to significantly increased ratios of Th1/Th2 and Th17/Treg. Additionally, the levels of certain cytokines were significantly higher in SSc patients. The findings contribute to a better understanding of the pathogenesis of SSc and provide a basis for the development of novel therapeutic interventions targeting these cells and cytokines.
FRONTIERS IN PHARMACOLOGY
(2022)